Last reviewed · How we verify

CC-122 — Competitive Intelligence Brief

CC-122 (CC-122) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunoproteasome inhibitor. Area: Oncology.

phase 2 Immunoproteasome inhibitor Immunoproteasome Oncology Small molecule Live · refreshed every 30 min

Target snapshot

CC-122 (CC-122) — Celgene. CC-122 is a selective inhibitor of the immunoproteasome.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
CC-122 TARGET CC-122 Celgene phase 2 Immunoproteasome inhibitor Immunoproteasome

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunoproteasome inhibitor class)

  1. Celgene · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CC-122 — Competitive Intelligence Brief. https://druglandscape.com/ci/cc-122. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: